Cancer Drug Withdrawal Raises Safety Concerns for Lymphoma Patients

New data linking tazemetostat to secondary blood cancers prompts global market withdrawal and trial discontinuation

A cancer drug used to treat certain lymphomas and sarcomas is being withdrawn worldwide after new trial data suggested a possible increased risk of secondary blood cancers. The decision highlights how accelerated approvals depend on confirmatory studies to verify long-term safety and benefit.

Study Details

Tazemetostat, marketed as Tazverik, is an oral ca…